{"title":"Physicochemical, ADMET Properties, and Molecular Docking Studies of N-Benzoyl-N’-Naphtylthiourea Derivatives for Anti-Breast Cancer Activity","authors":"D. Megawati, J. Ekowati, Siswandono Siswodihardjo","doi":"10.2174/1570180820666230817101819","DOIUrl":null,"url":null,"abstract":"\n\nN-benzoyl-N'-naphthylthiourea (BNTU) is a thiourea-derived compound that is predicted to have anti-breast cancer activity. However, their physicochemical properties, ADMET, and receptor-specific targets for their anti-breast cancer activity have not been reported.\nObjective: This study aimed to predict the physicochemical properties, ADMET, and anti-breast cancer activity of BNTU and its derivatives by in silico approach.\n\n\n\nThe physicochemical and ADMET properties were predicted using the pkCSM online program and ProTox-II online tool. While the anti-breast cancer activity was predicted using the molecular docking method through the Molegro Virtual Docker (MVD) program on the HER-2 receptor. The parameter observed in the molecular docking method was the bond energy value or rerank score (RS). Compounds with small RS values were predicted to have a great activity.\n\n\n\nMost BNTU derivatives had lower RS values than BNTU, especially 4TBBNTU, and 4CFBNTU, although their RS values were still higher than lapatinib and TAK-285. As for the reference ligand hydroxyurea, the RS value of BNTU and its derivatives was much lower. The physicochemical and pharmacokinetic properties (ADMET) of lapatinib and TAK-285 were not better than that of BNTU and its derivatives.\n\n\n\nFive compounds that deserve to be synthesized and tested for anti-breast cancer activity in vitro and in vivo are 4TBBNTU, 3CFBNTU, 4CFBNTU, 4OCBNTU, and the lead compound\n","PeriodicalId":18063,"journal":{"name":"Letters in Drug Design & Discovery","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Drug Design & Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1570180820666230817101819","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
N-benzoyl-N'-naphthylthiourea (BNTU) is a thiourea-derived compound that is predicted to have anti-breast cancer activity. However, their physicochemical properties, ADMET, and receptor-specific targets for their anti-breast cancer activity have not been reported.
Objective: This study aimed to predict the physicochemical properties, ADMET, and anti-breast cancer activity of BNTU and its derivatives by in silico approach.
The physicochemical and ADMET properties were predicted using the pkCSM online program and ProTox-II online tool. While the anti-breast cancer activity was predicted using the molecular docking method through the Molegro Virtual Docker (MVD) program on the HER-2 receptor. The parameter observed in the molecular docking method was the bond energy value or rerank score (RS). Compounds with small RS values were predicted to have a great activity.
Most BNTU derivatives had lower RS values than BNTU, especially 4TBBNTU, and 4CFBNTU, although their RS values were still higher than lapatinib and TAK-285. As for the reference ligand hydroxyurea, the RS value of BNTU and its derivatives was much lower. The physicochemical and pharmacokinetic properties (ADMET) of lapatinib and TAK-285 were not better than that of BNTU and its derivatives.
Five compounds that deserve to be synthesized and tested for anti-breast cancer activity in vitro and in vivo are 4TBBNTU, 3CFBNTU, 4CFBNTU, 4OCBNTU, and the lead compound
n -苯甲酰-n '-萘基硫脲(BNTU)是一种硫脲衍生化合物,预计具有抗乳腺癌活性。然而,它们的理化性质、ADMET和抗乳腺癌活性的受体特异性靶点尚未报道。目的:采用计算机模拟方法预测BNTU及其衍生物的理化性质、ADMET及抗乳腺癌活性。利用pkCSM在线程序和ProTox-II在线工具预测了其理化性质和ADMET性质。通过Molegro虚拟Docker (MVD)程序对HER-2受体进行分子对接,预测其抗乳腺癌活性。在分子对接方法中观察到的参数为键能值或重秩评分(RS)。预测RS值小的化合物具有较高的活性。大多数BNTU衍生物的RS值低于BNTU,尤其是4TBBNTU和4CFBNTU,尽管它们的RS值仍高于拉帕替尼和TAK-285。对于参考配体羟基脲,BNTU及其衍生物的RS值要低得多。拉帕替尼和TAK-285的理化药代动力学性质(ADMET)均不优于BNTU及其衍生物。值得合成并在体外和体内进行抗乳腺癌活性测试的化合物有4TBBNTU、3CFBNTU、4CFBNTU、4OCBNTU和先导化合物